Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours

NCT07341737 is registered in ClinicalTrials.gov with Second Life Therapeutics as lead sponsor.

NCT NCT07341737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07341737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours
Lead sponsor
Second Life Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 14, 2026
Completion date
March 1, 2027
Enrollment
60 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, breast cancer, colorectal cancer, endometrial cancer, esophageal cancer, head & neck cancer, intestinal cancer, liver cancer, lung adenocarcinoma, lung cancer (non-small cell), lung cancer (nsclc), melanoma (skin cancer), ovarian cancer, pancreas cancer, metastatic, pancreas carcinoma, prostate cancer, renal cancer, stomach (gastric) cancer